EB-D fibronectin expression in squamous cell carcinoma of the head and neck

MHAWECH-FAUCEGLIA, Paulette, et al.

Abstract
ED-B fibronectin (ED-B FN), a glycoprotein involved in cell adhesion and migration, is expressed in fetal and neoplastic tissues and absent in their normal counterparts. The aim of this study is to evaluate the expression of this glycoprotein in relation to the histological and clinical data and to determine whether it has a prognostic value in patients with head and neck squamous cell carcinoma (HNSCC). Ninety-five cases were assessed for ED-B FN expression using immunohistochemistry. Positive ED-B FN expression was significantly associated with tumor grade (p=0.06) and primary tumor site (p=0.02). The larynx was the tumor site associated with the least ED-B FN expression. In univariate analysis, there was no association with disease-free survival (p=0.48), but the mean time to progression was clearly shorter in tumors with positive ED-B FN expression than in those with negative expression (6 vs. 11 months). Patients having tumors expressing the ED-B FN had a trend to a significant lower overall survival in the multivariate analysis (p=0.06). Our study showed that ED-B FN expression might have a prognostic value in [...]
EB-D fibronectin expression in squamous cell carcinoma of the head and neck

Paulette Mhawecha,*, Pavel Dulguerovb, Mounia Assalya, Carmen Aresc, Abdelkarim S. Allalc

a Department of Pathology, Geneva University Hospital, CMU Michel-Servet 1, Geneva 1211, Switzerland
b Division of Head and Neck Surgery, Geneva University Hospital, CMU Michel-Servet 1, Geneva 1211, Switzerland
c Division of Radiation Oncology, Geneva University Hospital, CMU Michel-Servet 1, Geneva 1211, Switzerland

Received 6 May 2004; accepted 12 July 2004

Summary ED-B fibronectin (ED-B FN), a glycoprotein involved in cell adhesion and migration, is expressed in fetal and neoplastic tissues and absent in their normal counterparts. The aim of this study is to evaluate the expression of this glycoprotein in relation to the histological and clinical data and to determine whether it has a prognostic value in patients with head and neck squamous cell carcinoma (HNSCC). Ninety-five cases were assessed for ED-B FN expression using immunohistochemistry. Positive ED-B FN expression was significantly associated with tumor grade (p = 0.06) and primary tumor site (p = 0.02). The larynx was the tumor site associated with the least ED-B FN expression. In univariate analysis, there was no association with disease-free survival (p = 0.48), but the mean time to progression was clearly shorter in tumors with positive ED-B FN expression than in those with negative expression (6 vs. 11 months). Patients having tumors expressing the ED-B FN had a trend to a significant lower overall survival in the multivariate analysis (p = 0.06). Our study showed that ED-B FN expression might have a prognostic value in patients with HNSCC.

KEYWORDS

ED-B fibronectin expression; Head and neck squamous cell carcinoma; Immunohistochemistry; Prognostic value

Introduction

Despite the important advances made in the management of head and neck squamous cell carcinoma (HNSCC), patients still have a poor prognosis with a 5-year disease-free survival (DFS) of about 50%. The prognostic factors are mostly confined...
to the histopathologic and clinical parameters such as grade, stage, pattern of invasion, location, and lymph node metastasis.\textsuperscript{2–5} Recently, numerous molecular markers such as cell cycle regulators, cell adhesion proteins, oncogenes and tumor suppressor-genes have been investigated in HNSCC. Some of these markers have shown promising results for future use.\textsuperscript{6–8}

Fibronectin (FN) is a high-molecular mass adhesive glycoprotein; synthesized and secreted by numerous cell types, such as endothelial cells of neovasculature, stromal fibro/myofibroblasts, and tumor cells.\textsuperscript{9–12} It is involved in numerous functions including cell adhesion, migration, homeostasis, wound healing and oncogenic transformation.\textsuperscript{13,14} As shown by sequence analysis, FN is made up of three types of sequence homologies, types I, II, and III repeats, and has three sites of alternative splicing: ED-A (extra domain A), ED-B (extra domain B) and IIICS (type III homology connecting segment). Monoclonal antibodies against FN protein have been identified using immunohistochemistry (IHC); BC-1 and ED-A fibronectin, antibodies with a specific binding or recognition of the ED-B domain, and ED-A domain respectively and the glycosylated fibronectin antibodies such as FD-6 and 5C10, which define an oncofetal de novo O-linked glycosylation of the fibronectin molecule in the IIICS domain. However, studies have shown almost similar staining results using three different, 5C10, FD-6 and BC1, monoclonal antibodies.\textsuperscript{15,16}

ED-B FN, also designated as oncofetal FN, due to its presence in fetal and tumor tissues but not in their normal counterparts.\textsuperscript{17} Using IHC technique, numerous works have shown its expression in normal proliferative endometrium, chronic inflammatory diseases and ocular angiogenesis.\textsuperscript{18–20} In addition, ED-B FN was detected in numerous tumors, including brain, breast, colon, and head and neck squamous cell carcinoma.\textsuperscript{16,18,21,22} The intensity of FN staining in colorectal carcinoma has been associated with advanced local stage, liver metastasis and general prognosis.\textsuperscript{23} In oral carcinoma, FN expression seemed to be associated with lymph node metastasis and mortality.\textsuperscript{24}

Moreover, as a specific antibody (L19) with a high affinity to ED-B domain targeting the neovasculature in vivo has been identified, this antibody may have diagnostic and therapeutic values. It can be I-radio labeled (scFv) \textsuperscript{2}, so primary tumors as well as metastases may be detected, hence its potential use in imaging medicine.\textsuperscript{25} On the other hand, when this antibody is labeled with a photosensitizer, animal models showed its high efficacy in selectively targeting tumor neovasculature, resulting in occlusion of blood vessels and thus cell death.\textsuperscript{21} These data on animal models showed a promising use of the L19 antibody for future clinical trials.

The aim of this study is first to determine the levels of ED-B FN expression in HNSCC and their relationship with the histological and clinical data and second to assess its utility in predicting outcome of patients with HNSCC after curative treatment with radiotherapy (RT) with or without chemotherapy.

### Materials and methods

#### Patients population

A retrospective study covering 10 years (1992–2001) was conducted. Criteria for inclusion were patients with no prior treatment, histological diagnosis performed in our department and adequate material for analysis. Tumors with a nasopharyngeal origin were excluded from the study. Ninety-five patients were identified and selected for the present analysis. Patient and tumors characteristics are summarized in Table 1. After the initial diagnosis, patients were treated with radical RT with or without chemotherapy (see below). All patients were regularly followed up by the otolaryngologist, and the radio-oncologist. Treatment

<table>
<thead>
<tr>
<th align="left">Median age (years) [range]</th>
<th align="left">59 [35–85]</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Sex M:F</td>
<td align="left">77/18</td>
</tr>
<tr>
<td align="left">Tumor sublocation</td>
<td align="left"></td>
</tr>
<tr>
<td align="left">Oral cavity</td>
<td align="left">4</td>
</tr>
<tr>
<td align="left">Oropharynx</td>
<td align="left">58</td>
</tr>
<tr>
<td align="left">Hypopharynx</td>
<td align="left">21</td>
</tr>
<tr>
<td align="left">Larynx</td>
<td align="left">11</td>
</tr>
<tr>
<td align="left">Paranasal Sinus</td>
<td align="left">1</td>
</tr>
<tr>
<td align="left">TN classification and stages (UICC 1997)</td>
<td align="left"></td>
</tr>
<tr>
<td align="left">T1-2</td>
<td align="left">35</td>
</tr>
<tr>
<td align="left">T3-4</td>
<td align="left">60</td>
</tr>
<tr>
<td align="left">N0</td>
<td align="left">54</td>
</tr>
<tr>
<td align="left">N+</td>
<td align="left">41</td>
</tr>
<tr>
<td align="left">Stage I–II</td>
<td align="left">12</td>
</tr>
<tr>
<td align="left">Satge III–IV</td>
<td align="left">83</td>
</tr>
<tr>
<td align="left">Histology grading</td>
<td align="left"></td>
</tr>
<tr>
<td align="left">Well differentiated (G1)</td>
<td align="left">28</td>
</tr>
<tr>
<td align="left">Moderately differentiated (G2)</td>
<td align="left">42</td>
</tr>
<tr>
<td align="left">Poorly differentiated (G3)</td>
<td align="left">25</td>
</tr>
</tbody>
</table>
modalities and follow-up data were retrieved from the registry at the Division of Radiation Oncology. The median follow-up for the surviving patients was 44 months (range: 3–78).

Treatment

All patients received the same accelerated RT schedule using concomitant boost technique. The latter has been described previously in detail.26 The planned total dose was 69.9 Gy, delivered in 41 fractions over a period of 38 days. The basic course was given to a total dose of 50.4 Gy over 5.5 weeks. The boost to sites of initial macroscopic tumor involvement consisted of 19.5 Gy and was given as a second daily fraction, starting the last day of the second week of the basic treatment. According to our institutional policy,27 five patients (6%) underwent a planned neck dissection prior to RT, either radical or modified radical while one patient had simple excisions of lymph node metastases. Otherwise, surgery was reserved for salvage of locoregional failures.

Chemotherapy was given to 27 patients (28%), usually for patients presenting with T3-4 or N2-3 tumors if their medical condition was judged good enough to tolerate multimodality treatment. All patients received one or more cycles of cisplatin ±5-FU based chemotherapy concomitantly with RT.

Immunohistochemistry

Tissue analyzed consisted of initial (pretreatment) biopsies. The original diagnosis was reviewed by two pathologists (PM, MA) and the histological grade was assessed using the WHO system. Immunohistochemistry (IHC) was performed on paraffin-embedded tissues. Tissue sections were deparaffinized with xylene and washed with ethanol. The method used was the alkaline phosphatase–antialkaline phosphatase (APAAP) method. For immunostaining enhancement, pretreatment by microwave oven in 0.01M citrate buffer (pH 6.0) at 98°C for 20min was done. Sections were incubated overnight at 4°C with the antimurine BC-1 antibody, recognizing the ED-B oncofetal FN isoform and diluted at 1:100. Immunostaining was performed by using the streptavidin–biotin–alkaline phosphatase complex staining kit (Biogenex, Basel, Switzerland) and fast red kit (Hamburg, Germany) as substrate to visualize the binding sites. Tissue sections from poorly differentiated squamous cell carcinoma of the head and neck were taken as positive controls. Sections from normal tissue such as laryngeal mucosae, skin, breast and cervix, were used as negative controls. To test the specificity of the antibody, a normal goat serum was used in place of the primary antibody, resulting in a lack of detectable staining. Evaluation of the IHC was done by two pathologists (PM, MA) at a double head microscope who were neither aware of the original histological diagnosis nor of the clinical data. All the tissue on the slide was scanned for ED-B FN expression and cases were stratified in four categories negative, weak, medium and strong staining depending on the strength of intensity. Subsequently, cases were stratified in 2 groups; group 1 as negative (negative/weak expressions), group 2 as positive (medium/strong expressions).

Statistical analysis

The Fisher’s exact test was used to compare proportions and the two-tailed T-test to compare mean values of the different subgroups. The actuarial overall survival (OS) and disease-free survival (DFS) rates were calculated using the Kaplan–Meier method. For comparison between curves, the log-rank test was used. Multivariate analyses based on Cox proportional hazards standard model were used to identify the most significant factors related to outcomes. p-values of 0.05 or less were considered significant. All analysis was performed with the StatView V 5.0.1 software.

Results

Overall results

At last follow-up, 41 patients were alive, and 54 had died. Thirty-six patients presented with one or more events. Twenty-one patients presented with persistent or recurrent local disease, nine with regional disease (three regional only) and 13 with distant metastases (11 distant only). At 5 years, actuarial DFS was 54% (95% CI: 42–65%) and overall survival was 34% (95% CI: 23–46%).

ED-B fibronectin and clinico-pathologic associations

In normal ED-B FN expression was totally absent in squamous mucosae, skin, cervix, and breast tissue sections. On ED-B FN evaluation, 44 cases were ED-B FN positive and 51 cases were negative (Figs. 1a and b, and 2). In positive cases, ED-B FN was expressed in the stroma, blood vessels and some
tumor cells. FN was expressed in 32%, 45%, and 64% of G1, G2 and G3 cases respectively. Thus, there was a trend of significant association between ED-B FN expression and tumor grade ($p = 0.06$).

When the ED-B FN expression was compared with various clinical features, there was no significant association between the FN expression and T stage ($p = 0.99$) or lymph node status ($p = 0.41$). However, there was a significant association between FN expression and tumor sublocation (oropharynx in 53%, hypopharynx in 47% and larynx in 9%, $p = 0.02$).

**Univariate and multivariate analyses**

In the univariate analysis, advanced T- ($p = 0.034$) and N-categories ($p = 0.016$) were associated with a significantly lower 5-year DFS, while the expression of FN was not (54% vs. 53%, $p = 0.48$). However, the mean time to progression was shorter in patients with tumor expressing FN (6 vs. 11 months, $p = 0.13$).

For overall survival (OS), beside advanced T- ($p = 0.014$) and N-categories ($p = 0.04$), the expression of FN was significantly associated with lower 5-year survival rate (30% vs. 39%, $p = 0.046$) (Fig. 3). Histologic grading (G1 vs. G2-3) and treatment category (with or without chemotherapy) did not correlate significantly with DFS nor with OS.

Factors significantly influencing OS in univariate analysis were included in the Cox model (except linked variables). In such a model, T-category ($p = 0.004$) and N-category ($p = 0.018$) retained their significance for OS while fibronectin expression was of borderline significance ($p = 0.06$). The relative risks associated with these factors are listed in Table 2.
Discussion

Tumor stroma has been implicated to play a role in the invasive process of tumor by production of proteolytic enzyme and thus leading to the degradation of the extracellular matrix. In vitro studies showed the capability of ED-B FN to enhance adhesion and spreading of several cell types. In vivo studies showed the expression of ED-B FN expression in numerous tumor types such as colon, breast and oral carcinomas, and brain tumors. Furthermore, the generation of a mouse monoclonal antibody, BC-1, which proved to be a reliable and an easy tool to handle, has encouraged many to use it in clinical studies. Thus, the aim of our work is to determine the value of this protein in patients with HNSCC.

The first finding is the absence of ED-B FN staining in normal tissues such as normal laryngeal mucosae, skin, breast, endo and excocervical tissues; this is in agreement with the literature where no positive staining was seen. In our study, positivity for ED-B FN was found in the cytoplasm of tumor cells, in the stroma and the endothelial cells of neovasculature. This finding is in agreement with the literature, showing that the source of ED-B FN are fibro/myofibroblasts, endothelial cells during angiogenesis and tumor cells themselves. Furthermore, ED-B FN was present in 46% of cases, in accord with Lyons’ study where positivity was seen in 43% of cases.

As for the association of ED-B FN expression with the histological findings and the clinical data, among all parameters analyzed, including tumor grade, location, age, lymph node status, and UICC stage classification, only tumor location showed a significant association with ED-B FN expression. Therefore, tumors occurring in the larynx, which by far have better prognosis in comparison to those seen elsewhere, seemed to express ED-B FN to a lesser extent. This finding has not been described in earlier works. Furthermore, in those studies, tumor location was limited to the oral cavity or to the oropharynx, or simply was not stated. Second, ED-B FN expression did not show a significant association to tumor grade. This finding is in accord with others. In those studies, no association was seen between fibronectin expression and tumor grade. However, we must admit that, at the exception of Lyons’ study, the number of cases in each of these works was very small. Furthermore, despite the series of 100 cases analyzed by Lyons et al, the result was somewhat biased by the tumor sampling where the majority of tumors were moderately differentiated tumors. In our study, even though we did not find a significant association between ED-B FN expression and tumor grade, a trend of association was present between these two parameters. Meaning, that if we increase the number of cases, a significant association between ED-B FN and tumor grade will be observed.

As for DFS and overall survival, even though the association between FN expression and DFS is not significant, our data showed that there is a tendency towards shorter time to progression in ED-B FN positive tumors (6 vs. 11 months). Thus, those patients with tumors strongly positive for the ED-B FN are expected to progress in a shorter time period than those patients with negative tumor expression. In univariate analysis, there is a significant association between ED-B FN expression by the tumor and overall survival, and a significant trend of association in multivariate analysis. Patients whose tumors express ED-B FN are expected to have shorter overall survival after RT/chemotherapy. We assume that more aggressive the tumor becomes and greater the production of ED-B FN is expected to occur. This finding is in agreement with a study by Lyons et al., who showed a relation between fibronectin intensity and mortality, where patients with intense tumor staining had higher rate of mortality than those with less intense staining. However, in his study Lyons did not perform a multivariate analysis to look whether fibronectin could have an independent prognostic value. In our hand, we found that patients with tumors expressing ED-B FN had a trend to a significant association for lower overall survival in multivariate analysis. Meaning and once again, that if we

<table>
<thead>
<tr>
<th>Variables</th>
<th>RR</th>
<th>95% CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>T-category: T1-2/T3-4</td>
<td>0.41</td>
<td>0.22–0.75</td>
<td>0.004</td>
</tr>
<tr>
<td>N-category: N0/N1-3</td>
<td>0.51</td>
<td>0.29–0.89</td>
<td>0.018</td>
</tr>
<tr>
<td>Fibronectin expression: level 0–1/2–3</td>
<td>0.6</td>
<td>0.34–1.03</td>
<td>0.06</td>
</tr>
</tbody>
</table>

RR: relative risk; CI: confidence interval.
increase the number of our cases, this finding will be of greater significance.

We must emphasize that the comparison between different studies is somewhat difficult, and subject to errors due to numerous factors. (1) Some studies used fresh tissue and others used formalin-fixed tissue, as each method has its advantage and disadvantage; e.g., in fresh tissue, we may face the problem of sampling error. In addition, the technique and the result interpretation are somehow difficult and subject to variations in our opinion. On the other hand, in formalin-fixed tissue, we have a good tumor sampling, tissue is easier to handle and manipulate and the interpretation of staining is much accurate. However, we might risk losing some staining intensity. (2) Some of those studies used monoclonal antibodies directed against the glycosylated fibronectin such as FD-6 and 5C10 and others against the ED-B fibronectin such as BC1. However, Mandel et al. showed that using three different monoclonal antibodies FD-6, 5C10, and ED-B FN, the staining results in all cases were almost similar. Thus, despite the use of different antibodies, we can justify comparison among different studies. (3) Clinical data, location, grading and staging were not very clearly mentioned in the earlier studies, so comparison could not be made accurately. (4) Finally, the criteria used to define positivity for fibronectin expression was not homogenous in all the studies and most of the time was not stated.

In summary, ED-B FN expression in HNSCC might give us useful information on tumor behavior as it may identify patients at higher risk for shorter time to recurrence and for shorter or lower overall survival rate after therapy. However, these data have to be evaluated in a much larger more homogenous series of patients with HNSCC before further recommendations.

Acknowledgements

We would like to thank F. Ludicke, MD for providing the antibody, Mr. Ludovic Metral for his technical skills, Mrs. Louise Hanggeli for her technical assistance and for Dr. Sophia Taylor for her reading the manuscript.

References


